Integrated Approaches to Food Allergen and Allergy Risk Management
NCT ID: NCT02295397
Last Updated: 2017-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
72 participants
INTERVENTIONAL
2014-11-30
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In patients with a hazelnut or peanut allergy a double-blind placebo controlled food challenge with cookies containing either placebo or hazelnut and peanut respectively will be performed to determine threshold levels eliciting an allergic reaction. The results for threshold levels determined by cookie matrix will be compared to the results gained from the EuroPrevall project (matrix comparison study).
In patients with a walnut allergy double-blind placebo controlled provocation with walnut will be combined with the intake of proton pump inhibitor (PPI) or with placebo to assess the impact of PPI on the threshold level and on the clinical manifestation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Positive Food Challenge
NCT02786914
Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study
NCT02665793
Mixed Tree Nut Food Challenges
NCT02070263
The Feasibility of Systemic Reaction After Contact Exposure to the Allergenic Food in Children With Known Food Allergy
NCT05080127
Study to Assess Tolerance of Traces in Peanut/Tree Nut Allergic Children.
NCT03680066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. detailed case history, blood sampling and prick testing with different foods will performed.
2. food provocation with a chocolate dessert meal containing either hazelnut, walnut or celeriac (ED05) will be performed (single shot study) in patients with a positive case history of an allergic reaction to either hazelnut, walnut or celeriac or with two meals containing either placebo or hazelnut and peanut respectively in hazelnut and peanut allergic patients or with three meals containing either placebo or walnut in walnut allergic patients.
3. in patients with a negative single shot challenge an open provocation with native hazelnut, walnut, celeriac will be performed unless the patients do not have had a positive previous food provocation with the respective food. In patients with a negative double-blind placebo-controlled food challenge an open provocation with hazelnut or peanut or walnut will be performed to confirm tolerance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
food provocation
open and placebo-controlled food challenges
food
food provocation, skin testing, blood sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
food
food provocation, skin testing, blood sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For single shot study: history of a hazelnut, walnut, celeriac allergy due to an unequivocal accidental exposure with typical acute allergic reaction within the preceding 2 years and positive allergen-specific skin prick test/specific Immunoglobulin E or recent positive oral food challenge with hazel, walnut or celeriac within previous 2 years in children \<16 years, but no time limit specified for adults
* For matrix comparison study: history of peanut or hazelnut allergy
* For walnut/PPI study: history of walnut allergy. The minimum age for this study is 18 years
Exclusion Criteria
* Intake of Ketotifen (past 2 weeks), corticosteroids (past 2 weeks), histamine-1-receptor blocker (past 3 days apart first generation past 7 days)
* Anaphylactic reaction (past 4 weeks)
* Uncontrolled bronchial asthma, forced expiratory volume \< 70% predicted
* Pregnancy
* Acute infection or allergy
* Uncontrolled atopic dermatitis
* Chronic urticaria
* Mastocytosis
* Uncontrolled hypertension
5 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cork University Hospital
OTHER
Charite University, Berlin, Germany
OTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
University of Nebraska Lincoln
OTHER
Region Hovedstadens Apotek
OTHER_GOV
Servicio MadrileƱo de Salud, Madrid, Spain
OTHER
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clare Mills, Coordinator
Role: STUDY_CHAIR
University Manchester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allergy Unit, Department of Dermatology, University Hospital
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
iFAAM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.